0001728117-24-000076.txt : 20240624 0001728117-24-000076.hdr.sgml : 20240624 20240624175218 ACCESSION NUMBER: 0001728117-24-000076 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240621 FILED AS OF DATE: 20240624 DATE AS OF CHANGE: 20240624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hasnain Faheem CENTRAL INDEX KEY: 0001352620 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38796 FILM NUMBER: 241065627 MAIL ADDRESS: STREET 1: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Gossamer Bio, Inc. CENTRAL INDEX KEY: 0001728117 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 475461709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3013 SCIENCE PARK CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 922-0718 MAIL ADDRESS: STREET 1: 3013 SCIENCE PARK CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 wk-form4_1719265930.xml FORM 4 X0508 4 2024-06-21 0 0001728117 Gossamer Bio, Inc. GOSS 0001352620 Hasnain Faheem 3013 SCIENCE PARK ROAD SAN DIEGO CA 92121 1 1 0 0 President & CEO 0 Common Stock 2024-06-21 4 P 0 372000 0.6728 A 5408073 I By family trust Common Stock 120293 D The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 23,172 shares, with the Reporting Person's sale of 23,172 shares of common stock at a price of $1.1554 per share on March 27, 2024. The Reporting Person paid to the Issuer $11,349.86, representing the full amount of the profit realized in connection with the short-swing transaction. This transaction was executed in multiple trades at prices ranging from $0.6079 to $0.7217 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. /s/ Jeff Boerneke, Attorney-in-Fact 2024-06-24